ORI Capital Concludes Second Fund ORI Fund II with $260 Million in Commitments

ORI Capital announced today it has successfully completed the final close of ORI Fund II, attaining total commitments of $260 million. The fund's achievement of its original target highlights the strong confidence of investors in the firm's investment strategy and track record. 

The Fund will focus on investing in early-stage biotech companies globally, particularly in the areas of diagnostics, drug delivery, and therapeutics targeting significant unmet medical needs in diseases such as cancer, metabolic disorders, and neurodegenerative diseases. The investment team, with extensive experience in the biotech and healthcare sector, will utilize its ORIZON platform, driven by big data and AI, to source distinct investments and collaborate with companies to enhance value creation.

Simone Song, Founding Partner, commented:

We are in a golden-era of innovation across the intersection of AI and biology, where technological breakthroughs are creating new approaches to diagnosing and treating diseasel.

We believe the current environment provides an attractive opportunity for investing in the next generation of leading biotech companies. Through our big data and AI-enabled ORIZON platform, we seek to be a capital provider of choice, to help founders and companies bring their innovative therapies and technologies to patients. We prioritize investments in companies tackling significant diseases with high mortality rates.

The Fund seeks to deploy capital supporting new biological approaches including RNA targeting small molecules, protein degradation and stabilization, the programmable nuclear acid therapies such as DNA and RNA therapies, immuno-oncology cell therapy, and synthetic biology.

The firm has achieved notable exits through IPOs and acquisitions, including CG Oncology, Kymab, Semma Therapeutics, Orchard Therapeutics, and TriSalus Life Sciences.

Read the full press release here.